Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740743 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL10349992 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL17259193 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL742488 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL5543830 | 1.00 | HRH1 (0.68) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL1288240 | 0.98 | TDP1 (0.67) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL294520 | 0.92 | CYP2A6 (0.66) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL29485634 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL2845851 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 | |
| SCHEMBL29485667 | 0.90 | HRH1 (0.81) | HRH1TBXAS1TDP1L3MBTL1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0503426-B1 | Quinone derivatives | EISAI CO LTD (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0619807-A1 | NEW BHT ETHER COMPOUNDS AND THEIR USE AS HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC DRUGS | MERTZ + CO., GMBH & CO (DE) | 1994-10-19 | — | — | EP | disclosed |
| US-5329010-A | Unsaturated groups with heteroarylalkyl groups and carboxy derivatives | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| US-5300524-A | Spirocyclic PAF antagonists | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-04-05 | — | — | US | disclosed |
| US-5254549-A | New BHT ether compounds and their use as hypolipidemic and antiatherosclerotic drugs | MERZ & CO. GMBH & CO. (DE) | 1993-10-19 | — | — | US | disclosed |
| WO-1993012089-A1 | NEW BHT ETHER COMPOUNDS AND THEIR USE AS HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC DRUGS | MERZ + CO., GMBH & CO. (DE) | 1993-06-24 | — | — | WO | disclosed |
| WO-1992015571-A1 | 1-OXA-2,9-DIPHENYL-SPIRO(4,4)NONANE DERIVATIVES AS PAF ANTAGONISTS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-09-17 | — | — | WO | disclosed |
| EP-0503426-A1 | Quinone derivatives | Eisai Co., Ltd. (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0502706-A1 | 1-Oxa-2,9-diphenyl-spiro[4.4]nonane derivatives as PAF antagonists | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HRH1 668/4885TBXAS1 2580/4885TDP1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.